Xtant Medical Holdings, Inc. (XTNT) Earnings Call Transcripts

Xtant Medical Holdings, Inc.'s Latest Earnings Call - Q4 FY2025

In the fourth quarter of 2025, Xtant Medical Holdings, Inc. (XTNT) reported revenue of $32.4 million, a 3% increase year-over-year, and a full-year revenue of $133.9 million, reflecting a 14% growth from 2024. The company achieved positive net income of $57,000 for the quarter and $5 million for the full year, marking a significant turnaround from losses in the previous year. Management provided guidance for 2026, projecting revenue between $99 million, indicating a focus on organic growth in their core biologics business despite headwinds from divested assets and license revenue expiration.

Reported metrics

Guidance from management

Management expects 2026 revenue to be approximately $99 million, reflecting organic growth in the core biologics business despite anticipated declines from divested assets and license revenue expiration.

What management said

Yes. I simply say that we've already seen a decline in the hardware that remains post divestiture, and we expect that, that decline will continue at a reasonably steady rate approaching high teens in 2026. .

And then a couple as we think kind of longer term, Sean, as we think about kind of direct your distribution network, white label, potentially kind of some larger contracts with institutions. Like where do you see over the medium term, your business kind of showing the most growth? Is it these white label contracts? Is it continuing to be in your distribution network just some thoughts there as far as kind of where yo...

What analysts pressed on

Analysts expressed concerns regarding the expected decline in the hardware business, with one analyst asking, "How quickly do you guys expect to see a decline in the hardware business throughout 2026?" There is also apprehension about the impact of lost license revenue on overall growth.

Main topics on the call

• Revenue Performance — Xtant Medical achieved fourth-quarter revenue of $32.4 million, up 3% from $31.5 million in Q4 2024. Full-year revenue reached $133.9 million, toward the upper end of guidance of $131 million to $135 million, indicating ...
• Net Income Improvement — The company reported net income of $57,000 for Q4 2025, a significant improvement from a net loss of $3.2 million in Q4 2024. For the full year, net income was $5 million compared to a loss of $16.5 million in 2024, demo...
• Guidance for 2026 — Management anticipates 2026 revenue in the range of $99 million, reflecting the impact of divestitures and the expiration of license revenues. They expect organic growth in the core biologics business as new products gai...
• Product Launches and Innovation — Xtant launched new products including Manos Strata and Collagen X, which are expected to enhance their biologics portfolio. Sean Browne noted, "Early surgeon feedback has been excellent," indicating strong market interes...

Read the full Xtant Medical Holdings, Inc. transcript (Q4 FY2025) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 27 Xtant Medical Holdings, Inc. earnings call transcripts on record, spanning March 5, 2020 to August 11, 2026. Based on this history, Xtant Medical Holdings, Inc. reports quarterly. The most recent call on file is dated August 11, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

XTNT

Exchange

NYSEAM

Country

US

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

27

First call

March 5, 2020

Most recent

August 11, 2026

Reporting cadence

quarterly